IL-2 is approved for treatment of advanced renal cell carcinoma (RCC) (9) and metastatic melanoma (10).IFN-α is approved for treatment of follicular lymphoma (11), hairy cell leukemia (12), AIDS-related Kaposi’s sarcoma (13), and melanoma (14). Here, IL2 is linked to metastatic melanoma.